The aim of the this PrEP guideline is to explain what PrEP is, outline current indications for its use, outline steps for appropriate user selection and provide guidance to monitor and maintain PrEP users.
This document is a corrigendum to our "Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update".
This guideline is an update of the post-exposure prophylaxis (PEP) guideline published by the Southern African HIV Clinicians Society in 2008.
These guidelines are an update of the Southern African HIV Clinicians Society’s ART 2014 guidelines. The update is to the section of the adult ART guidelines relating to when ART should be initiated.
UPDATED:Algorithms which assist in managing infants with indeterminate HIV PCR results.
Update to 2007 guidance to include all types of migrants and crisis-affected populations, including those forcibly displaced. This update stresses that migration and forced displacement must NO T be used as an excuse to deny treatment. Clear recommendations are provided for states, clinicians and programme managers, civil society, donors and United Nations (UN ) agencies.
2014 update to the Society guideline on adult antiretroviral therapy.
This document is provided as an information resource for all health care workers to assist in the appropriate prescribing of antibiotics.
Guideline on mental health disorders and CNS sequelae in HIV positive children and adolescents
A reference document to assist HIV nurse and doctor clinicians in managing mental health disorders
Practical guidance on the re-introduction of anti-TB drugs and ART in HIV/TB co-infected individuals presenting with DILI
Updated to include newly available drug formulations: ABC 60mg dispersible tablets and ABC (60mg) + 3TC (300mg) tablets
Update to 2007 guidelines on the prevention, diagnosis and management of cryptoccocal meningitis among HIV-infected persons
Guidance on how to switch patients from 3 separate antiretroviral (ARV) drugs to the new, single, FDC tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV).
Recommendations for HIV resistance testing for people living with HIV in the southern African region
Guidelines include new data on antiretroviral (ARV) tolerability in the region and on new ARV drugs. Guidelines on third-line (or ‘salvage’) therapy have been expanded.
If your facility is experiencing a lopinavir/ritonavir stock out then please follow this guidance.
Due to drug stock outs of tenofovir (TDF) and abacavir (ABC) across the country, the Society has developed some guidance for clinicians in order to ensure that no HIV infected South African currently on this treatment suffers because of these stock outs.